Joseph Stringer
Stock Analyst at Needham
(4.87)
# 340
Out of 4,516 analysts
609
Total ratings
48.4%
Success rate
25.2%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Rated: Buy | $11 → $25 | $5.55 | +350.45% | 37 | Jul 15, 2026 | |
| IONS Ionis Pharmaceuticals | Rated: Buy | $105 → $86 | $54.93 | +56.56% | 42 | Jul 9, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $40 | $29.13 | +37.32% | 45 | Jul 9, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $50 | $22.78 | +119.49% | 5 | Jul 9, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | n/a | $476.31 | - | 32 | Jul 7, 2026 | |
| PCVX Vaxcyte | Maintained: Buy | $110 | $56.21 | +95.69% | 41 | Jun 26, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $510 | $281.26 | +81.33% | 47 | Jun 24, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $130 | $109.96 | +18.22% | 47 | Jun 15, 2026 | |
| GILD Gilead Sciences | Rated: Buy | $170 | $130.04 | +30.73% | 30 | Jun 12, 2026 | |
| STTK Shattuck Labs | Rated: Buy | $14 → $17 | $6.29 | +170.27% | 5 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $11.04 | +153.74% | 73 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.09 | - | 33 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $9.49 | +89.67% | 46 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $46 | $67.44 | -31.88% | 42 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.12 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.10 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.92 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $25.49 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $172.04 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $50.46 | n/a | 2 | Apr 28, 2021 |
Annexon
Jul 15, 2026
Rated: Buy
Price Target: $11 → $25
Current: $5.55
Upside: +350.45%
Ionis Pharmaceuticals
Jul 9, 2026
Rated: Buy
Price Target: $105 → $86
Current: $54.93
Upside: +56.56%
Stoke Therapeutics
Jul 9, 2026
Maintained: Buy
Price Target: $40
Current: $29.13
Upside: +37.32%
BioAge Labs
Jul 9, 2026
Maintained: Buy
Price Target: $50
Current: $22.78
Upside: +119.49%
Vertex Pharmaceuticals
Jul 7, 2026
Maintained: Hold
Price Target: n/a
Current: $476.31
Upside: -
Vaxcyte
Jun 26, 2026
Maintained: Buy
Price Target: $110
Current: $56.21
Upside: +95.69%
Alnylam Pharmaceuticals
Jun 24, 2026
Maintained: Buy
Price Target: $510
Current: $281.26
Upside: +81.33%
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $130
Current: $109.96
Upside: +18.22%
Gilead Sciences
Jun 12, 2026
Rated: Buy
Price Target: $170
Current: $130.04
Upside: +30.73%
Shattuck Labs
Jun 8, 2026
Rated: Buy
Price Target: $14 → $17
Current: $6.29
Upside: +170.27%
Jun 1, 2026
Maintained: Buy
Price Target: $28
Current: $11.04
Upside: +153.74%
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $1.09
Upside: -
May 7, 2026
Maintained: Buy
Price Target: $18
Current: $9.49
Upside: +89.67%
May 1, 2026
Maintained: Hold
Price Target: $46
Current: $67.44
Upside: -31.88%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $2.12
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $3.10
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $16.92
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $25.49
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $172.04
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $50.46
Upside: n/a